Drug intelligence / Profile preview

Lan taoye total alkaloids capsule

Development stage: Unknown
Lead developer: Kunming Institute of Botany
Modality: Small Molecules
Administration: Oral

Overview

Lan taoye total alkaloids capsule is a botanical drug candidate developed by the Kunming Institute of Botany, Chinese Academy of Sciences. It contains a total alkaloid fraction extracted from the plant *Heliotropium indicum* (commonly known in China as Lan taoye). The drug is being developed for the treatment of respiratory inflammatory conditions, specifically acute tracheobronchitis and acute exacerbations of chronic bronchitis. It is designed as an improved oral formulation (capsule) compared to existing Lan taoye tablets. Clinical development has reached Phase 1, with studies focusing on the pharmacokinetics and safety of single and multiple oral doses in healthy Chinese adults.

Other names: Lan taoye total alkaloids蓝塔叶总生物碱胶囊

Beyond the preview

Go deeper on Lan taoye total alkaloids capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lan taoye total alkaloids capsule.

Explore the full profile